Drug Manufacturers

Cipla to exclusively market and distribute five Pfizer brands in India

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Generic drugmakers to slash price plans as Novo cuts Wegovy rates

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

Centre refuses deadline extension for pharma firms after Coldrif deaths

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

Dr Reddy's launches 'Tegoprazan' in India for acid peptic diseases

Tegoprazan, a next-generation acid blocker, offers faster relief and lasting control for GERD, NERD, and gastric ulcers, addressing India's rising acid peptic disease burden

China's biotech surge shifts global drug innovation, stirs US tension

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough designations as they gain confidence in China's biotech innovation

Drugmakers may lose product licence if govt labs flag quality failures

The Health Ministry is working with states to allow immediate suspension of licences for drugs declared substandard by labs, following a key recommendation from Drugs Technical Advisory Board

Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Serum Institute signs MoU with DNDi to develop dengue treatment candidate

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, Brazil and other endemic countries

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Booster shot as India's pharma market grew 8.4% in FY25: Pharmarack

Augmentin remains top-selling medicine brand at Rs 816 crore sales

Higher tariffs may significantly dent profits of pharma companies

Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments

Drugmakers tout AI efforts at conference amid US tariffs concerns

Drugmakers such as Amgen and contract manufacturers including Parexel highlighted AI's role in reducing the time taken to conduct certain parts of the trials

Trump threatens drugmakers with tariffs if they don't move production to US

Trump also didn't commit to pushing Congress to water down a drug pricing programme enacted under President Joe Biden that the pharmaceutical industry has been seeking relief from

CDSCO flags 135 drugs for failing quality standards for December 2024

Most drugs found NSQ by central labs this month were produced in units located in cities such as Ahmedabad, Vadodara, Himachal Pradesh's Baddi, Puducherry, Roorkee and Haridwar

Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors

111 drug samples tested in November found 'not of standard quality': CDSCO

Central Drugs Standard Control Organisation (CDSCO) has found 41 drug samples tested in the central drug laboratories in November as 'not of standard quality' (NSQ), official sources said. Besides, 70 drug samples tested by the state drugs testing laboratories have also been identified as NSQ in November, they said. Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters. "The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns on the other drug products available in the market," an official said. Two drug samples were identified as spurious drugs in November. Out of the two samples, one was picked by Bihar Drugs Control Authority and the other by CDSCO, Ghaziabad, the sources said. The drugs were made by unauthorised and unknown manufacturers, using brand names of other companies. Action to identify NSQ and spurious medicines is ta

AstraZeneca withdraws EU application for experimental lung cancer drug

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not significantly improve overall survival for patients

Ex Pfizer CEO, CFO not to involve in Starboard's campaign on drugmaker

Pfizer's shares have fallen more than 9% in the past year and trade at around half of their pandemic-era highs as sales of its COVID products shrink

'India's pharma exports expected to remain strong amid global slowdown'

Exports of India's pharmaceutical and meditech sectors are expected to sustain the growth momentum in the ongoing fiscal despite a slowdown in the global economy, a senior government official said on Wednesday. With the government revving up support for drug development in India, as many as 16 blockbuster molecules targeted for a wide range of therapeutic areas, including cancer, diabetes, HIV and tuberculosis, are in the pipeline to be produced in India, Department of Pharmaceuticals, Secretary Arunish Chawla told reporters on the sidelines of CII Pharma and Life Sciences summit here. "We have been analysing the export trends in the recent data. Even though there is a general slowdown in exports globally, the good news is that the Indian pharmaceuticals, biotech, and bulk drug exports have grown double-digit over the last year," he said in response to a query on export prospects of the pharma industry amid a global slowdown. He further said,"In the first four months of this year, .